Please assess the completion status of the following clinical trial:

Trial Title: Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* women~* post-menopausal age~* class I-II obesity~* normal thyroid, liver, and kidney function~Exclusion Criteria:~* type 2 diabetes mellitus~* use of hypolipaemic agents

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- orlistat plus normo-caloric diet (Type: None): 10 subjects received normo-caloric diet plus + orlistat (Xenical, Roche, UK) at a dose of 120 mg tid. The duration of follow-up was 10 days
- normo-caloric diet (Type: None): 10 subjects received normo-caloric diet without the additional treatment. The duration of follow-up was 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).